Other Information
+Added: On November 8, 2023, we delivered written notice to Jefferies LLC that we were terminating the prospectus supplement, dated October 1, 2021, related to our common stock, $0.0001 par value per share, issuable pursuant to the terms of the Open Market Sale Agreement SM , dated October 1, 2021, between us and Jefferies LLC, or the ATM Agreement, and terminating the ATM Agreement.
+Added: Pursuant to the terms of the ATM Agreement, the ATM Agreement will terminate on November 22, 2023 (10 trading days from the delivery of our notice of termination), or the Termination Date.
+Added: The ATM Agreement provided for the offer and sale of shares of our common stock, from time to time, through an “at the market offering” program having an aggregate offering price of up to $75.0 million through which Jefferies LLC would act as sales agent.
+Added: All of the continuing obligations under the ATM Agreement will terminate as of the Termination Date, other than those provisions which expressly survive termination as provided in the ATM Agreement.
+Added: We are not subject to any termination penalties related to the termination of the ATM Agreement.
+Added: Prior to termination, we sold 5,925 shares of common stock under the ATM Agreement resulting in net proceeds of approximately $34,000.
+Added: The foregoing description of the ATM Agreement is not complete and is qualified in its entirety by reference to the full text of the ATM Agreement, a copy of which was filed as Exhibit 1.2 to our Registration Statement on Form S-3 (File No.
+Added: 333-259966) filed with the SEC on October 1, 2021.
EXHIBIT INDEX
5 unchanged sentences
(incorporated by reference to Exhibit 3.1 to our Current Report on Form 8K filed October 6, 2020).
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunome, Inc., dated October 2, 2023, to implement Officer Exculpation (incorporated by reference to Exhibit 3.3 to our Current Report on Form 8-K filed October 4, 2023).
+Added: Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Immunome, Inc., dated October 2, 2023, to implement Authorized Share Increase (incorporated by reference to Exhibit 3.4 to our Current Report on Form 8-K filed October 4, 2023).
Amended and Restated Bylaws of Immunome, Inc.
(incorporated by reference to Exhibit 3.2 to our Current Report on Form 8K filed October 6, 2020) .
−Removed: Form of Immunome, Inc.
−Removed: Stockholder Support Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed June 29, 2023).
−Removed: Form of Morphimmume, Inc.
−Removed: Stockholder Support Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed June 29, 2023).
−Removed: Form of Lock-Up Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed June 29, 2023).
−Removed: Form of Subscription Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed June 29, 2023).
−Removed: Employment Agreement, dated June 28, 2023, by and between Immunome, Inc.
−Removed: Siegall, Ph.D.
−Removed: (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K filed June 29, 2023).
+Added: Form of Common Stock Certificate (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form S-1 filed September 24, 2020).
+Added: Amended and Restated Investors’ Rights Agreement by and among Immunome, Inc.
+Added: and certain of its stockholders, dated June 2, 2020 (incorporated by reference to Exhibit 4.1 to our Registration Statement on Form S-1 filed September 9, 2020).
+Added: 202 0 Immunome, Inc.
+Added: Equity Incentive Plan, as amended.
+Added: Third Amended and Restated Non-Employee Director Compensation Policy, effective October 27, 2023.
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2023 filed in XBRL).
+Added: Interactive Data File (Form 10-Q for the Quarterly Period ended September 30, 2023 filed in XBRL).
The financial information contained in the XBRL-related documents is "unaudited"
6 unchanged sentences
IMMUNOME, INC.
−Removed: August 9, 2023
−Removed: /s/ Purnanand D.
+Added: November 9, 2023
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: August 9, 2023
+Added: November 9, 2023
/s/ Corleen M.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.